经导管瓣中瓣主动脉瓣置换作为外科再次置换的替代选择
基于法国2010–2019年全国住院数据库,倾向性评分匹配后各717例分析,比较瓣中瓣TAVR与再次SAVR治疗主动脉生物瓣失败。30天复合终点(全因死亡、卒中、心梗、大出血)VIV TAVR更低(OR 0.62,95%CI 0.44–0.88,p=0.03);中位516天随访主要心血管复合终点两组无差异(OR 1.18,95%CI 0.99–1.41,p=0.26),VIV TAVR心衰再住院与起搏器植入更多。
要点
- VIV TAVR短期复合终点优于再次SAVR(OR 0.62,95%CI 0.44–0.88,p=0.03)。
- 长期主要心血管复合终点两组无差异(OR 1.18,95%CI 0.99–1.41,p=0.26)。
- VIV TAVR组心衰再住院和起搏器植入更常见。
核心结论
- VIV TAVR短期结局优于再次SAVR,长期主要心血管结局两组无差异。
研究设计与样本
- 基于法国行政住院出院数据库的全国性研究,纳入2010–2019年因主动脉生物瓣失败接受孤立VIV TAVR或再次SAVR的患者。
- 数据库共找到4327例患者,倾向性评分匹配后每组717例进行分析。
主要发现
- 30天时VIV TAVR与全因死亡、全因卒中、心肌梗死、重大或危及生命出血复合终点发生率更低相关(OR 0.62,95%CI 0.44–0.88,p=0.03)。
- 中位随访516天,心血管死亡、全因卒中、心肌梗死或心衰再住院复合终点两组无差异(OR 1.18,95%CI 0.99–1.41,p=0.26)。
- VIV TAVR组心衰再住院和起搏器植入报告更频繁。
- VIV TAVR后全因和心血管死亡率存在时间依赖性交互作用(p-interaction <0.05)。
临床怎么用
- 对于主动脉生物瓣失败患者,VIV TAVR可作为再次SAVR的替代选择,尤其关注短期安全性。
- 需权衡VIV TAVR组更高的心衰再住院和起搏器植入风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) and redo surgical aortic valve replacement (SAVR) represent the 2 treatments for aortic bioprosthesis failure. Clinical comparison of both therapies remains limited by the number of patients analyzed. OBJECTIVES: The purpose of this study was to analyze the outcomes of VIV TAVR versus redo SAVR at a nationwide level in France. METHODS: Based on the French administrative hospital-discharge database, the study collected information for patients treated for aortic bioprosthesis failure with isolated VIV TAVR or redo SAVR between 2010 and 2019. Propensity score matching was used for the analysis of outcomes. RESULTS: A total of 4,327 patients were found in the database. After matching on baseline characteristics, 717 patients were analyzed in each arm. At 30 days, VIV TAVR was associated with lower rates of the composite of all-cause mortality, all-cause stroke, myocardial infarction, and major or life-threatening bleeding (odds ratio: 0.62; 95% confidence interval: 0.44 to 0.88; p = 0.03). During follow-up (median 516 days), the combined endpoint of cardiovascular death, all-cause stroke, myocardial infarction, or rehospitalization for heart failure was not different between the 2 groups (odds ratio: 1.18; 95% confidence interval: 0.99 to 1.41; p = 0.26). Rehospitalization for heart failure and pacemaker implantation were more frequently reported in the VIV TAVR group. A time-dependent interaction between all-cause and cardiovascular mortality following VIV TAVR was reported (p-interaction <0.05). CONCLUSIONS: VIV TAVR was observed to be associated with better short-term outcomes than redo SAVR. Major cardiovascular outcomes were not different between the 2 treatments during long-term follow-up.
引用
- Deharo P, Bisson A, Herbert J, et al. Transcatheter Valve-in-Valve Aortic Valve Replacement as an Alternative to Surgical Re-Replacement. J Am Coll Cardiol. 2020. PMID: 32731926. doi:10.1016/j.jacc.2020.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。